AC Immune (NASDAQ:ACIU) Trading Down 1.3% – What’s Next?

Shares of AC Immune (NASDAQ:ACIU) dropped 1.3% on Wednesday . The company traded as low as $2.20 and last traded at $2.27. 245,506 shares were traded during trading, a decline of 4% from the average daily volume of 255,854 shares. The stock had previously closed at $2.30.

Analyst Ratings Changes

A number of brokerages have recently issued reports on ACIU. Weiss Ratings downgraded shares of AC Immune from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, May 8th. BTIG Research reaffirmed a “buy” rating and issued a $8.00 price target on shares of AC Immune in a report on Monday, May 4th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of AC Immune in a research report on Wednesday, July 1st. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, AC Immune presently has a consensus rating of “Hold” and an average price target of $7.50.

AC Immune Trading Down 0.7%

The stock has a market cap of $226.44 million, a PE ratio of -2.71 and a beta of 1.57. The company’s fifty day moving average is $2.48 and its 200-day moving average is $2.86. The company has a debt-to-equity ratio of 0.11, a current ratio of 0.87 and a quick ratio of 1.02.

AC Immune (NASDAQ:ACIU) last announced its quarterly earnings results on Thursday, April 30th. The company reported ($0.19) earnings per share for the quarter, beating the consensus estimate of ($0.20) by $0.01. The company had revenue of $1.40 million during the quarter, compared to analysts’ expectations of $0.33 million. AC Immune had a negative return on equity of 125.26% and a negative net margin of 1,788.02%. On average, analysts predict that AC Immune will post -0.84 earnings per share for the current fiscal year.

Insider Transactions at AC Immune

In other news, CEO Andrea Pfeifer sold 10,000 shares of the company’s stock in a transaction on Friday, May 15th. The shares were sold at an average price of $2.79, for a total transaction of $27,900.00. Following the completion of the sale, the chief executive officer owned 3,820,288 shares of the company’s stock, valued at $10,658,603.52. This represents a 0.26% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 4.60% of the stock is currently owned by company insiders.

Institutional Trading of AC Immune

Several large investors have recently bought and sold shares of the business. Marshall Wace LLP acquired a new stake in AC Immune during the fourth quarter worth about $586,000. Dimensional Fund Advisors LP boosted its holdings in AC Immune by 82.8% in the 1st quarter. Dimensional Fund Advisors LP now owns 390,165 shares of the company’s stock valued at $1,071,000 after purchasing an additional 176,701 shares during the last quarter. Acadian Asset Management LLC grew its stake in shares of AC Immune by 87.1% in the 1st quarter. Acadian Asset Management LLC now owns 371,177 shares of the company’s stock valued at $679,000 after buying an additional 172,796 shares during the period. Arrowstreet Capital Limited Partnership increased its holdings in shares of AC Immune by 8.0% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 405,658 shares of the company’s stock worth $1,116,000 after buying an additional 30,035 shares during the last quarter. Finally, Sei Investments Co. acquired a new stake in shares of AC Immune during the 2nd quarter worth approximately $51,000. Hedge funds and other institutional investors own 51.36% of the company’s stock.

AC Immune Company Profile

AC Immune AG is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland, with a subsidiary in Boston, Massachusetts. The company specializes in the discovery and development of therapeutics and diagnostics for neurodegenerative diseases, with a primary focus on Alzheimer’s disease, Parkinson’s disease and other protein misfolding disorders. AC Immune leverages proprietary platform technologies to identify and optimize candidates that target pathological protein aggregates.

Since its founding in 2003, AC Immune has advanced multiple programs into clinical development.